Kia ora,   We are writing regarding funded diabetes technology, specifically insulin pump choice, and quantity limitations for continuous glucose monitors (CGMs), and the process to follow when encountering faulty devices.   Insulin pump choice Since October 2024, Pharmac has funded two insulin pumps for people meeting eligibility criteria. A table comparing the various features and differences between the two pumps  is on the Pharmac website. Pump selection is considered ‘p

From 1 November 2025, Pharmac will be updating its rare disorders policy principles by broadening the definition of a rare disorder. The new definition will be: “a medical condition with a specific pattern of clinical signs, symptoms and findings that affects fewer than or equal to 1 in 2,000 people in Aotearoa New Zealand.” This change aligns Pharmac’s policy with the Aotearoa New Zealand Rare Disorders Strategy 2024 and reflects the feedback we received from stakeholders a

We want your feedback on a proposal to fund silver diamine fluoride for people accessing dental services through Health New Zealand public hospitals, and the ‘Health New Zealand Community Oral Health Service’ for children and some adolescents. Silver diamine fluoride is a topical dental treatment, combining ionic silver and fluoride. It can stop the progression of existing cavities and reduce tooth sensitivity. It is used in hospitals and community dental clinics and can only

Kia ora   We are writing to inform you of a supply issue.   Key messages The supplier Pfizer has informed us that Depo-Testosterone will be in short supply from late-October to mid-December 2025. Pfizer has been unable to source an alternative bioequivalent product. Please consider not starting any new patients on Depo-Testosterone for the supply issue period Clinical advice has told us - prescribers may wish to consider alternative funded testosterone products , such as Rean

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 17 October 2025. It includes information on:  New updates Resolved Supply Issues Pharmac has confirmed changes to Special Authority renewal requirements for selected medicines and products.From 1 December 2025, Pharmac will remove the need to renew Special Authority approvals for the following treatments: Insulin pump consumables for type 1 diabetes

Humapen Savvio: Update  Eli Lilly has made changes to how it supplies its Humapen Savvio insulin pen.  Imiquimod: New look  (Pharmacode: 2543907) Imiquimod is changing packaging style from a sachet to a "stick". Pictures and a patient flyer are available. Rizatriptan (Rizamelt) dispersible tab 10 mg  (Pharmacode: 2394634) Due to an increase in demand and delays at the factory, there is a supply issue affecting Rizamelt tablets.  Rosuvastatin (10 mg, 20 mg, 40 mg tablets)  Via

Kia ora, Pharmac is now consulting publicly on a proposal to bring greater clarity and transparency to how we manage medicine funding applications on the Options for Investment (OFI) list. We’re proposing to decline some of the lowest-ranked applications that have remained on the OFI list for more than two years, as they are unlikely to be funded under current priorities. This change aims to help people better understand our funding intentions and support more informed decisi

Pharmac has confirmed changes to Special Authority renewal requirements for selected medicines and products. From 1 December 2025, Pharmac will remove the need to renew Special Authority approvals for the following treatments: Insulin pump consumables for type 1 diabetes Continuous glucose monitors (interoperable and standalone) for type 1 diabetes Long-acting Muscarinic Antagonists with Long-acting Beta-Adrenoceptor Agonists (LAMA/LABA inhalers) for respiratory conditions Ep

We are writing to inform you that Pharmac is expecting a constrained supply of oxytocin injection 10 IU per mL, 1 mL ampoule (Pharmacode:...

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week...

Candesartan cilexetil (Candestar) Tab 32 mg  (Pharmacode: 2380439) Due to delays at the factory, the supplier is out of stock of this...

This link  will take you to the proposal to enter into an agreement with Obex Medical Limited (“Obex”) for medical devices in the...

From the 1 November 2025, Pharmac will be widening access to ticagrelor, a blood-thinning medicine that helps prevent blood clots, for...

Discontinuation:   We are writing to inform you that Sanofi is discontinuing supply of ketoprofen (Oruvail) SR Capsules 200mg.    Key...

Pharmac Decision: Changes to support increased prescription lengths  Please follow this link  to the Pharmac decision regarding changes...

New community medicine notices Chloramphenicol eye drops: Chlorsig is changing to Chlorafast  (Pharmacode: 335142) Chlorsig eye drops are...

Proposal to change funding criteria and supply arrangements for antiretroviral medicines used to treat HIV Pharmac is now consulting...

Proposal to change funding criteria and supply arrangements for antiretroviral medicines used to treat HIV Pharmac is now consulting...

We are writing to inform you of that there has been a delay with a recent shipment of Condyline solution 0.5%   Key messages: AFT...

Tender results Kia ora, Please find attached the 29 September 2025 Tender Notification . Ngā mihi,  Stefanie Moir | Tender Analyst Te...